899503

FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Temporary FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL

OMB NUMBER:

3235-0076

Expires:

March 15, 2009

Estimated average burden

hours per response......4.00

PROCESSED

MAR 2 7 2009

Name of Offering (check if this is an amendment of Common Stock	ent and name has changed, and indicate change.)	I	THOMSON REUTERS
Filing Under (Check box(€s) that apply): Type of Filing: ■ New Filing □ Amendment	□ Rule 504 □ Rule 505 ■ Rule 506 □ Section	4(6) □ ULOE	SEC Mail Processing Section
	A. BASIC IDENTIFICATION DATA		MAR 1 1 cocc
1. Enter the information requested about the issu	ет		MAN 112009
Name of Issuer (check if this is an amendment Alseres Pharmaceuticals, Inc.	and name has changed, and indicate change.)	_	Washington, DC 111
Address of Executive Offices (Number and	Street, City, State, Zip Code)	Telephone Number	r (Including Area Code)
239 South Street, Hopkinton, MA 01748	, ,	508-497-2360	
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number	r (Including Area Code)
Brief Description of Business:			
development stage biotechnology company eng diseases and cancer.	gaged in the research and development of novel therap	eutic and diagnostic	solutions for central nervous system
Type of Business Organization			
■ corporation	☐ limited partnership, already formed	□ other (please spe	x(fy).
☐ business trust	☐ limited partnership, to be formed	<u></u>	
	Month Year anization 10 92 ■ Actual □ Estimated anter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction)	DE	09035475
GENERAL INSTRUCTIONS			

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Two (2) copies of this notice must be filed with the SEC, one of which must be manually signed. The copy not manually signed must be a photocopy of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA				
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 							
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Course Potent C							
Savas, Peter G. Business or Residence Address	(Number and S	Street, City, State, Zip Coo	le)				
- ""	•		/				
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street, Ho						
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Pykett, Mark J.							
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	ie)				
	4.0						
c/o Alseres Pharmaceuticals, Inc., 239 S Check Box(es) that Apply:		Beneficial Owner	■ Executive Officer	= D:			
Full Name (Last name first, if individual)	□ Promoter	D Beneficial Owner	Executive Officer	☐ Director	☐ General and/or Managing Partner		
Tan Name (Last mane 1115), it maividual)							
Rice, Jr., Kenneth L.							
Business or Residence Address	(Number and St	treet, City, State, Zip Cod	e)				
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street. Ho	nkinton MA 01748					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Langer, Robert Business or Residence Address	(Number and S	Street, City, State, Zip Coo	(a)				
Business of Residence Address	(Number and 5	incer, City, State, Zip Coc	iej				
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street, Ho	pkinton, MA 01748					
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Mullen, Michael J.							
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	le)				
			,				
c/o Alseres Pharmaceuticals, Inc., 239 S Check Box(es) that Apply:				·			
Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
run Name (Last name mst, it muividuat)							
Preston, John T.							
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)				
c/o Alseres Pharmaceuticals, Inc., 239 Se	outh Street Ho	nkinton MA 01749					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)	<u>G 110motes</u>	B Delicitoral Owner	B Excent Connect	- Director	Constanting of Williams		
Guinness, William L.S.	<u> </u>	0: 0: 0: 0: 0: 0		_ 			
Business or Residence Address	Business or Residence Address (Number and Street, City, State, Zip Code)						
c/o Alseres Pharmaceuticals, Inc., 239 South Street, Hopkinton, MA 01748							

□ Executive Officer

■ Director

☐ General and/or Managing Partner

☐ Beneficial Owner

(Number and Street, City, State, Zip Code)

Check Box(es) that Apply:

Business or Residence Address

Brem, Henry

Full Name (Last name first, if individual)

□ Promoter

c/o Alseres Pharmaceuticals, Inc., 239 South Street, Hopkinton, MA 01748

		A. BASIC IDENT	IFICATION DATA			
2. Enter the information requested for t						
	 Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; 					
Each executive officer and directions						
Each general and managing par			general and managing pe	naicis of paraicis	inp issues, und	
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)	□ Pioinoter	□ Beneficial Owner	□ Executive Officer	■ Director	Oeneral and/of Managing Farther	
Tan Name (Last hame inst, it narvidual)						
Frashier, Gary E.			<u>, , </u>			
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)			
c/o Alseres Pharmaceuticals, Inc., 239 S	outh Street, Ho	pkinten, MA 01748				
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Gipson, Robert L. Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)			
Dushies of Residence Address	(remote and 5	arca, Ony, Blate, 23p Coc				
c/o Ingalis & Snyder LLC, 61 Broadway	y, New York, N	Y 10006			<u></u>	
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	□Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Gipson, Thomas L.						
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)			
	•		,			
c/o Ingalls & Snyder LLC, 61 Broadway Check Box(es) that Apply:						
	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Ingalis & Snyder LLC				_		
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)			
61 Broadway, New York, NY 10006						
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)					2 other and the managers and the	
,						
Ingalls & Snyder Value Partners, LP Business or Residence Address	(March 1)	The City City City City City	1.			
Business or Residence Address	(Number and a	Street, City, State, Zip Co	aej			
61 Broadway, New York, NY 10006						
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	□ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Koenig, Arthur						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			
	(.		· -			
c/o Duferco Steel Inc., Metro Park Sout	h <u>, 100 Matawa</u> i	Road, Suite 400, Mata	wan, NJ 07747			
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			

ı

	B. INFORMATION ABOUT OFFERING		
	Yes	No	
1.	D	•	
2.	Answer also in Appendix, Column 2, if filing under ULOE. What is the minimum investment that will be accepted from any individual?	\$ <u>n/a</u>	
		Yes	No
3.	Does the offering permit joint ownership of a single unit? Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or		
4.			
Full Non	Name (Last name first, if individual)		
	iness or Residence Address (Number and Street, City, State, Zip Code)		
D431	mas of Residence Address (Mainter and Breef, Chy, Baile, 24p Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		-
	(,	All States	(15)
_ []	MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer	<u></u>	
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers	 ,	
	(Check "All States" or check individual States)	All States	
_ [! _ [! _ [!		_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)		<u> </u>
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
_ [] _ []	AL) _[AK] _[AZ] _[AR] _[CA] _[CO] _[CT] _[DE] _[DC] _[FL] _[GA] IL] _[IN] _[IA] _[KS] _[KY] _[LA] _[ME] _[MD] _[MA] _[MI] _[MN] MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK] RI] _[SC] _[SD] _[TN] _[TX] _[UT] _[VT] _[VA] _[WA] _[WV] _[WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS $% \left(\mathbf{r}\right) =\left(\mathbf{r}\right)$

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box cand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	S	s
	Equity	\$ 200,000	\$ 200,000
	■ Common □ Preferred		
	Convertible Securities (including warrants)	s	\$
	Partnership Interests	\$	s
	Other (Specify)	s	s
	Total	\$200,000	\$ <u>200,000</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	1	\$ <u>200,000</u>
	Non-accredited Investors		s
	Total (for filings under Rule 504 only)	<u> </u>	<u> </u>
	Answer also in Appendix, Column 4, if filing under ULOE		-
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		s
	Regulation A		s
	Rule 504	 -	\$
	Total		s
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		-
	Transfer Agent's Fces	n	s
	Printing and Engraving Costs	 O	s
	Legal Fees	_	\$ 10,000
	Accounting Fees	0	\$
	Engineering Fees		s
	Sales Commissions (specify finders' fees separately)		s
	Other Expenses (identify)		•
			£ 10.000
	Total		\$ <u>10,000</u>

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

•	I and total expenses furnished in respon-	regate offering price given in response to Part C – se to Part C – Question 4.a. This difference is the	•		S	190,000	
5,	for each of the purposes shown. If the ar and check the box to the left of the estim	d gross proceeds to the issuer used or proposed to mount for any purpose is not known, furnish an estate. The total of the payments listed must equal the forth in response to Part C - Question 4.5 above.	aimate				
				Payments to Officers, Directors, & Affiliates		Payments To Others	
	Salaries and fees		a	s	a	\$	
	Purchase of real estate		o	s	0	s	
	Purchase, rental or leasing and installation	n of machinery and equipment	a	\$	۵	s	
	Construction or leasing of plant building	s and facilities	a	s	o	s	
		the value of securities involved in this offering					
		ets or securities of another issuer pursuant to a	0	\$	a	s	
	Repayment of indebtedness	***************************************	a	s	а	s	
	Working capital	***************************************	c)	s	•	\$ 190,000	
	Other (specify):			s	a	s	
							
			à	\$	a	s	
	Column Totals	***************************************	•	s <u> </u>	_	\$ 190,000	
	Total Payments Listed (column totals added)			a \$	190.000		
		,				<u>-</u>	
		D. FEDERAL SIGNATU	RE				
n un	suer has duly caused this notice to be sig dertaking by the issuer to furnish to the U ceredited investor pursuant to paragraph (ned by the undersigned duly authorized person. I S. Securities and Exchange Commission, upon w (b)(2) of Rule 502.	f this notice witten reques	is filed under Rule 505, the I st of its staff, the information	ollowing s	signature constitutes by the issuer to any	
			\				
	(Print or Type)	Signature	= \	Dato			
	es Pharmaceuticals, Inc.		<u> </u>	February 26, 2009			
ame	of Signer (Print or Type)	Title of Signer (Print or Type)					
		_ ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `					

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

